Department of Infectious Diseases, Xi'an Jiaotong University Affiliated Children's Hospital, No. 69 Xi Ju Yuan Alley, Xi'an, 710003, Shaanxi, China.
Department of Infectious Diseases, the Second Affiliated Hospital Xi'an Jiaotong University, No.157 Xi Wu Road, Xi'an, 710004, Shaanxi, China.
Eur J Pediatr. 2024 May;183(5):2353-2363. doi: 10.1007/s00431-024-05495-6. Epub 2024 Mar 2.
There are increasing reports of neurological manifestation in children with coronavirus disease 2019 (COVID-19). However, the frequency and clinical outcomes of in hospitalized children infected with the Omicron variant are unknown. The aim of this study was to describe the clinical characteristics, neurological manifestations, and risk factor associated with poor prognosis of hospitalized children suffering from COVID-19 due to the Omicron variant. Participants included children older than 28 days and younger than 18 years. Patients were recruited from December 10, 2022 through January 5, 2023. They were followed up for 30 days. A total of 509 pediatric patients hospitalized with the Omicron variant infection were recruited into the study. Among them, 167 (32.81%) patients had neurological manifestations. The most common manifestations were febrile convulsions (n = 90, 53.89%), viral encephalitis (n = 34, 20.36%), epilepsy (n = 23, 13.77%), hypoxic-ischemic encephalopathy (n = 9, 5.39%), and acute necrotizing encephalopathy (n = 6, 3.59%). At discharge, 92.81% of patients had a good prognosis according to the Glasgow Outcome Scale (scores ≥ 4). However, 7.19% had a poor prognosis. Eight patients died during the follow-up period with a cumulative 30-day mortality rate of 4.8% (95% confidence interval (CI) 1.5-8.1). Multivariate analysis revealed that albumin (odds ratio 0.711, 95% CI 0.556-0.910) and creatine kinase MB (CK-MB) levels (odds ratio 1.033, 95% CI 1.004-1.063) were independent risk factors of poor prognosis due to neurological manifestations. The area under the curve for the prediction of poor prognosis with albumin and CK-MB was 0.915 (95%CI 0.799-1.000), indicating that these factors can accurately predict a poor prognosis. Conclusion: In this study, 32.8% of hospitalized children suffering from COVID-19 due to the Omicron variant infection experienced neurological manifestations. Baseline albumin and CK-MB levels could accurately predict poor prognosis in this patient population. What is Known: • Neurological injury has been reported in SARS-CoV-2 infection; compared with other strains, the Omicron strain is more likely to cause neurological manifestations in adults. • Neurologic injury in adults such as cerebral hemorrhage and epilepsy has been reported in patients with Omicron variant infection. What is New: • One-third hospitalized children with Omicron infection experience neurological manifestations, including central nervous system manifestations and peripheral nervous system manifestations. • Albumin and CK-MB combined can accurately predict poor prognosis (AUC 0.915), and the 30-day mortality rate of children with Omicron variant infection and neurological manifestations was 4.8%.
越来越多的报告显示,儿童感染 2019 年冠状病毒病(COVID-19)后会出现神经表现。然而,感染奥密克戎变异株的住院儿童的频率和临床结局尚不清楚。本研究旨在描述因奥密克戎变异株感染而住院的 COVID-19 患儿的临床特征、神经表现和与预后不良相关的危险因素。参与者包括年龄大于 28 天且小于 18 岁的儿童。患者于 2022 年 12 月 10 日至 2023 年 1 月 5 日期间招募,并随访 30 天。共有 509 名因奥密克戎变异株感染住院的儿科患者纳入研究。其中,167(32.81%)例患儿有神经表现。最常见的表现为热性惊厥(n=90,53.89%)、病毒性脑炎(n=34,20.36%)、癫痫(n=23,13.77%)、缺氧缺血性脑病(n=9,5.39%)和急性坏死性脑病(n=6,3.59%)。出院时,92.81%的患儿根据格拉斯哥预后量表(GOS)(评分≥4 分)预后良好。然而,7.19%的患儿预后不良。8 例患儿在随访期间死亡,30 天累积死亡率为 4.8%(95%可信区间 1.5-8.1)。多变量分析显示白蛋白(比值比 0.711,95%可信区间 0.556-0.910)和肌酸激酶同工酶 MB(CK-MB)水平(比值比 1.033,95%可信区间 1.004-1.063)是神经表现不良预后的独立危险因素。白蛋白和 CK-MB 预测不良预后的曲线下面积为 0.915(95%CI 0.799-1.000),表明这些因素可以准确预测不良预后。结论:在本研究中,因奥密克戎变异株感染而住院的 COVID-19 患儿中有 32.8%出现神经表现。基线白蛋白和 CK-MB 水平可准确预测该患者人群的不良预后。已知:• SARS-CoV-2 感染可导致神经损伤;与其他株相比,奥密克戎株更易导致成人出现神经表现。• 已有报道称奥密克戎变异株感染的成年人出现脑出血和癫痫等神经系统损伤。未知:• 三分之一因奥密克戎感染住院的儿童出现神经表现,包括中枢神经系统表现和周围神经系统表现。• 白蛋白和 CK-MB 联合可准确预测不良预后(AUC 0.915),奥密克戎变异株感染伴神经表现的儿童 30 天死亡率为 4.8%。